234 related articles for article (PubMed ID: 31596908)
21. Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.
Summerer I; Hess J; Pitea A; Unger K; Hieber L; Selmansberger M; Lauber K; Zitzelsberger H
BMC Genomics; 2015 Sep; 16(1):654. PubMed ID: 26328888
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation.
Howard JD; Lu B; Chung CH
Oral Oncol; 2012 Jan; 48(1):10-7. PubMed ID: 22020057
[TBL] [Abstract][Full Text] [Related]
23. A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome, and miRNome analysis.
Jung AC; Job S; Ledrappier S; Macabre C; Abecassis J; de Reyniès A; Wasylyk B
Clin Cancer Res; 2013 Aug; 19(15):4174-84. PubMed ID: 23757353
[TBL] [Abstract][Full Text] [Related]
24. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
25. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.
Wheeler SE; Egloff AM; Wang L; James CD; Hammerman PS; Grandis JR
PLoS One; 2015; 10(2):e0117781. PubMed ID: 25658924
[TBL] [Abstract][Full Text] [Related]
26. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
27. Targeted Therapy of Head and Neck Cancer.
Rieke DT; Klinghammer K; Keilholz U
Oncol Res Treat; 2016; 39(12):780-786. PubMed ID: 27889751
[TBL] [Abstract][Full Text] [Related]
28. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
29. Leveraging Genomics for Head and Neck Cancer Treatment.
Kemmer JD; Johnson DE; Grandis JR
J Dent Res; 2018 Jun; 97(6):603-613. PubMed ID: 29420101
[TBL] [Abstract][Full Text] [Related]
30. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
van Dijk LK; Boerman OC; Kaanders JH; Bussink J
Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452
[TBL] [Abstract][Full Text] [Related]
31. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
Theurer JA; Stecho W; Yoo J; Kwan K; Wehrli B; Harry V; Black M; Pinto N; Winquist E; Palma D; Richter S; Barrett JW; Danielle MacNeil S; Fung K; Howlett CJ; Nichols AC
Pathol Oncol Res; 2016 Jan; 22(1):35-40. PubMed ID: 26271341
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas.
Szabó B; Nelhubel GA; Kárpáti A; Kenessey I; Jóri B; Székely C; Peták I; Lotz G; Hegedus Z; Hegedus B; Füle T; Döme B; Tímár J; Tóvári J
Oral Oncol; 2011 Jun; 47(6):487-96. PubMed ID: 21498106
[TBL] [Abstract][Full Text] [Related]
33. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
[TBL] [Abstract][Full Text] [Related]
34. Antitumor miR-150-5p and miR-150-3p inhibit cancer cell aggressiveness by targeting SPOCK1 in head and neck squamous cell carcinoma.
Koshizuka K; Hanazawa T; Kikkawa N; Katada K; Okato A; Arai T; Idichi T; Osako Y; Okamoto Y; Seki N
Auris Nasus Larynx; 2018 Aug; 45(4):854-865. PubMed ID: 29233721
[TBL] [Abstract][Full Text] [Related]
35. Subpath analysis of each subtype of head and neck cancer based on the regulatory relationship between miRNAs and biological pathways.
An F; Zhang Z; Xia M; Xing L
Oncol Rep; 2015 Oct; 34(4):1745-54. PubMed ID: 26239836
[TBL] [Abstract][Full Text] [Related]
36. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.
Peng CH; Liao CT; Ng KP; Tai AS; Peng SC; Yeh JP; Chen SJ; Tsao KC; Yen TC; Hsieh WP
Oncotarget; 2015 Aug; 6(23):19891-906. PubMed ID: 26087196
[TBL] [Abstract][Full Text] [Related]
37. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
38. Defining the genomic landscape of head and neck cancers through next-generation sequencing.
Rizzo G; Black M; Mymryk JS; Barrett JW; Nichols AC
Oral Dis; 2015 Jan; 21(1):e11-24. PubMed ID: 24725020
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of head and neck cancer: how close to personalized targeted therapy?
Worsham MJ; Ali H; Dragovic J; Schweitzer VP
Mol Diagn Ther; 2012 Aug; 16(4):209-22. PubMed ID: 22873739
[TBL] [Abstract][Full Text] [Related]
40. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Bowles DW; McDermott JD; Jimeno A
Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
